Literature DB >> 2987950

Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors.

J Fujita, S K Srivastava, M H Kraus, J S Rhim, S R Tronick, S A Aaronson.   

Abstract

Members of the ras gene family are activated as oncogenes in many different human cancers. To systematically determine the frequency at which such genes might be involved in the neoplastic process affecting a specific target tissue, urothelial cells, we surveyed a large series of urinary tract tumors for ras oncogenes by DNA transfection and by molecular genetic analysis. Harvey (Ha)-ras oncogenes were detected in 2 of 38 tumors by transfection, molecularly cloned in biologically active form, and shown to contain single base changes at codon 61 leading to substitutions of arginine and leucine, respectively, for glutamine at this position. One additional Ha-ras oncogene was identified in a bladder carcinoma by restriction polymorphisms at codon 12. In one of 21 tumors, we observed a 40-fold amplification of the Kirsten (Ki)-ras gene. No amplification of other ras genes was detected in any of the tumors analyzed. Our findings strengthen the conclusion that codons 12 and 61 are the major "hot spots" of ras oncogene activation and suggest that quantitative alterations in expression due to gene amplification may provide an alternative mechanism for ras gene activation in primary human tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987950      PMCID: PMC397885          DOI: 10.1073/pnas.82.11.3849

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Biological properties of human c-Ha-ras1 genes mutated at codon 12.

Authors:  P H Seeburg; W W Colby; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Nov 1-7       Impact factor: 49.962

3.  Mechanism of activation of a human oncogene.

Authors:  C J Tabin; S M Bradley; C I Bargmann; R A Weinberg; A G Papageorge; E M Scolnick; R Dhar; D R Lowy; E H Chang
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

4.  T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes.

Authors:  E Santos; S R Tronick; S A Aaronson; S Pulciani; M Barbacid
Journal:  Nature       Date:  1982-07-22       Impact factor: 49.962

5.  Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses.

Authors:  C J Der; T G Krontiris; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

Review 6.  Oncogenes of spontaneous and chemically induced tumors.

Authors:  R A Weinberg
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

7.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.

Authors:  E P Reddy; R K Reynolds; E Santos; M Barbacid
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

8.  Identification of a sarcoma virus-coded phosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine sarcoma virus.

Authors:  T Y Shih; M O Weeks; H A Young; E M Scholnick
Journal:  Virology       Date:  1979-07-15       Impact factor: 3.616

9.  Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene.

Authors:  L F Parada; C J Tabin; C Shih; R A Weinberg
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

10.  Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus.

Authors:  E H Chang; M E Furth; E M Scolnick; D R Lowy
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

View more
  37 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

Review 2.  Oncogenes and urological malignancies: implications for the future.

Authors:  J A Schalken; A M van den Ouweland; F M Debruijne; H F Karthaus; W J Van de Ven
Journal:  Urol Res       Date:  1988

3.  Detection of ras oncogenes by analysis of p21 proteins in human tumor cell lines.

Authors:  J Fujita; O Yoshida; Y Ebi; H Nakayama; H Onoue; J S Rhim; Y Kitamura
Journal:  Urol Res       Date:  1988

4.  Unexpected effects on bacterial phenotype induced by expression of a tumour-amplified human sequence.

Authors:  J Heighway; M F Santibanez-Koref
Journal:  Nucleic Acids Res       Date:  1989-09-12       Impact factor: 16.971

5.  Analysis of metastatic competence of mouse bladder carcinoma cells after transfection with activated Ha-ras or N-ras oncogenes.

Authors:  J Pohl; A Radler-Pohl; L M Franks; V Schirrmacher
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 6.  Human cancer and cellular oncogenes.

Authors:  S Nishimura; T Sekiya
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

Review 7.  Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.

Authors:  C Cordon-Cardo; J Sheinfeld
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

8.  Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.

Authors:  D Theodorescu; I Cornil; B J Fernandez; R S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 9.  Cancer genes: rare recombinants instead of activated oncogenes (a review).

Authors:  P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

10.  K-RAS mutation in transitional cell carcinoma of urinary bladder.

Authors:  S Ayan; G Gokce; H Kilicarslan; O Ozdemir; E Yildiz; E Y Gultekin
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.